Stockscreener 앱 받기
5.32
0.37%
-0.02
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Yahoo Finance
(ACRV) Trading Signals - Stock Traders Daily
Brokers Set Expectations for ACRV FY2024 Earnings - MarketBeat
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - MSN
Acrivon Therapeutics Inc (ACRV) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Acrivon Therapeutics announces FDA granted BDD for ACR-368 - Yahoo Finance
Research Analysts Offer Predictions for ACRV FY2024 Earnings - Defense World
The -10.05% Simple Moving Average of Acrivon Therapeutics Inc’s (ACRV) Stock in the Past 200 Days - The News Heater
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status - Insider Monkey
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
ACR-368 OncoSignature assay gains FDA breakthrough status - MSN
12 AI News and Ratings Investors are Keeping Their Eye On - Insider Monkey
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer - MSN
Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation - Marketscreener.com
Acrivon Therapeutics, Inc. Announces FDA Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - Marketscreener.com
Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification - Marketscreener.com
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
ACR-368 OncoSignature assay gains FDA breakthrough status By Investing.com - Investing.com UK
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 - The Bakersfield Californian
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated at KeyCorp - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Research Coverage Started at Cantor Fitzgerald - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at KeyCorp - Defense World
Head-To-Head Analysis: Jazz Pharmaceuticals (NASDAQ:JAZZ) & Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 6.3% - MarketBeat
JPMorgan Chase & Co. Has $238,000 Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight -January 31, 2025 at 08:14 am EST - Marketscreener.com
(ACRV) Trading Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average PT from Brokerages - Defense World
Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 6.3% in December - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(ACRV) On The My Stocks Page - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Growth in Short Interest - MarketBeat
Geode Capital Management LLC Has $2.12 Million Stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Investment Report - Stock Traders Daily
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
State Street Corp Acquires 47,233 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Brokerages - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Sells 27,705 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
2.40%
0.40%
자본화:
|
볼륨(24시간):